The Library
A novel dual-functioning ruthenium(II)–arene complex of an anti-microbial ciprofloxacin derivative — anti-proliferative and anti-microbial activity
Tools
Tools
Tools
Ude, Ziga, Romero-Canelón, Isolda, Twamley, Brendan, Fitzgerald Hughes, Deirdre, Sadler, P. J. and Marmion, Celine J. (2016) A novel dual-functioning ruthenium(II)–arene complex of an anti-microbial ciprofloxacin derivative — anti-proliferative and anti-microbial activity. Journal of Inorganic Biochemistry, 160 . pp. 210-217. doi:10.1016/j.jinorgbio.2016.02.018
|
PDF
WRAP_1-s2.0-S0162013416300435-main.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1003Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.jinorgbio.2016.02.018
Abstract
7-(4-(Decanoyl)piperazin-1-yl)-ciprofloxacin, CipA, (1) which is an analogue of the antibiotic ciprofloxacin, and its ruthenium(II) complex [Ru(η6-p-cymene)(CipA-H)Cl], (2) have been synthesised and the x-ray crystal structures of 1·1.3H2O·0.6CH3OH and 2·CH3OH·0.5H2O determined. The complex adopts a typical pseudo-octahedral ‘piano-stool’ geometry, with Ru(II) π-bonded to the p-cymene ring and σ-bonded to a chloride and two oxygen atoms of the chelated fluoroquinolone ligand. The complex is highly cytotoxic in the low μM range and is as potent as the clinical drug cisplatin against the human cancer cell lines A2780, A549, HCT116, and PC3. It is also highly cytotoxic against cisplatin- and oxaliplatin-resistant cell lines suggesting a different mechanism of action. The complex also retained low μM cytotoxicity against the human colon cancer cell line HCT116p53 in which the tumour suppressor p53 had been knocked out, suggesting that the potent anti-proliferative properties associated with this complex are independent of the status of p53 (in contrast to cisplatin). The complex also retained moderate anti-bacterial activity in two Escherichia coli, a laboratory strain and a clinical isolate resistant to first, second and third generation β-lactam antibiotics.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QD Chemistry R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Science > Chemistry | ||||||||
| Library of Congress Subject Headings (LCSH): | Ruthenium, Ciprofloxacin, Antineoplastic agents, Anti-infective agents | ||||||||
| Journal or Publication Title: | Journal of Inorganic Biochemistry | ||||||||
| Publisher: | Elsevier Science Inc | ||||||||
| ISSN: | 0162-0134 | ||||||||
| Official Date: | July 2016 | ||||||||
| Dates: |
|
||||||||
| Volume: | 160 | ||||||||
| Page Range: | pp. 210-217 | ||||||||
| DOI: | 10.1016/j.jinorgbio.2016.02.018 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Open Access | ||||||||
| Funder: | Science Foundation Ireland (SFI), European Research Council (ERC), Engineering and Physical Sciences Research Council (EPSRC) | ||||||||
| Grant number: | 11/RFP.1/CHS/ 3095, 12/TIDA/B2384 (SFI), 247450 (ERC), EP/F042159/1 (EPSRC) |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
